BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-03
191 industry Phase 2/3 trial readout(s) and 56 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-03 est. | P2 | United BioPharma UTHR | NCT03164447 UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients | HIV-1 Infection | unknown | 10 |
| 2024-03 est. | P2 | DBV Technologies DBVT | NCT04492683 Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy in Children | Cow's Milk Allergy | unknown | 230 |
| 2024-03 est. | P2 | Amnio Technology, LLC | NCT04667416 Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities | Chronic Ulcer of Lower Extremity | unknown | 82 |
| 2024-03 est. | P2 | Lutris Pharma Ltd. | NCT04759664 LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC | EGFRI Induced Acneiform Lesions | unknown | 117 |
| 2024-03 est. | P2 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | NCT05063253 A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes | Type 2 Diabetes Mellitus | unknown | 208 |
| 2024-03 est. | P2 | Clinuvel Europe Limited CUVL | NCT05159752 A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP) | Xeroderma Pigmentosum | unknown | 6 |
| 2024-03 est. | P2 | Theratocular Biotek Co. | NCT05390840 A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related M | Age-Related Macular Degeneration | unknown | 36 |
| 2024-03 est. | P2 | Cellevolve Bio Inc | NCT05541549 A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML | Progressive Multifocal Leukoencephalopathy | unknown | 60 |
| 2024-03 est. | P2 | Vyant Bio | NCT05625568 Study of VYNT-0126 in the Treatment of Rett Syndrome in Adult Patients | Rett Syndrome | unknown | 48 |
| 2024-03 est. | P3 | EQRx International, Inc. | NCT05712941 Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial | Endometrial Carcinoma | withdrawn | |
| 2024-03 est. | P2 | Krystal Biotech, Inc. KRYS | NCT05735158 Topical KB105 for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) | Autosomal Recessive Ichthyosis | unknown | 15 |
| 2024-03 est. | P3 | AIM Vaccine Co., Ltd. | NCT05812014 Clinical Trail of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) in Participants Aged 18 Years and Older | SARS-CoV-2 | unknown | 9800 |
| 2024-03 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT05863325 A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | unknown | 80 |
| 2024-03 est. | P2 | Baiya Phytopharm Co., Ltd. BIYA | NCT05873374 Evaluation of Safety, Tolerability, Reactogenicity, Immunogenicity of Baiya SARS-CoV-2 Vax 2 as a Booster for COVID-19 | COVID-19 Vaccine; COVID-19 | unknown | 75 |
| 2024-03 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05970432 A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis | Atopic Dermatitis | unknown | 160 |
| 2024-03 est. | P3 | Sinocelltech Ltd. | NCT06041061 A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years | HPV InfectioN; HPV-Related Carcinoma | active not recruiting | 18000 |
| 2024-03-01 est. | P3 | Angionetics Inc. | NCT02928094 Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia | Angina, Stable | unknown | 160 |
| 2024-03-01 | P2 | USWM CT, LLC | NCT03967223 Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors | Neoplasms | active not recruiting | 103 |
| 2024-03-01 | P2 | Cerebral Therapeutics LLC | NCT04153175 Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalizat | Refractory Epilepsy | terminated | 30 |
| 2024-03-01 | P2 | Marker Therapeutics, Inc. MRKR | NCT04511130 Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant | Acute Myeloid Leukemia; Stem Cell Transplantation | terminated | 92 |
| 2024-03-01 | P1/P2 | Cerebral Therapeutics LLC | NCT04529954 Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion | Focal Epilepsy | terminated | 20 |
| 2024-03-01 est. | P3 | Delcath Systems Inc. DCTH | NCT05022901 An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | Metastatic Ocular Melanoma; Metastatic Uveal Melanoma | active not recruiting | 30 |
| 2024-03-01 | P1/P2 | SK Life Science, Inc. | NCT05388435 Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Advanced Solid Tumor | terminated | 15 |
| 2024-03-01 est. | P2 | Mabwell (Shanghai) Bioscience Co., Ltd. | NCT05446688 A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma | Lymphoma | unknown | 40 |
| 2024-03-01 est. | P2 | Keymed Biosciences Co.Ltd | NCT05452343 A Study of CM310 in Subjects With Chronic Pruritus | Chronic Pruritus of Unknown Origin | unknown | 50 |
| 2024-03-01 | P2/P3 | Fenix Innovation Group | NCT05626959 Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder | Autism Spectrum Disorder | completed | 54 |
| 2024-03-01 est. | P2 | Sinovac Life Sciences Co., Ltd. | NCT06042764 SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients | Infection of Upper Respiratory Tract Caused by 2019-nCoV | unknown | 150 |
| 2024-03-01 | P3 | POLYSAN Scientific & Technological Pharmaceutical Company | NCT06183229 Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza | Influenza; Acute Respiratory Infection | completed | 166 |
| 2024-03-01 | P2 | USWM CT, LLC | NCT06703346 Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic | Neoplasms | completed | 82 |
| 2024-03-04 | P2 | Pfizer PFE | NCT03765073 Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women An | Group B Streptococcus Infections | completed | 1208 |
| 2024-03-04 | P1/P2 | Enterome | NCT04116658 First-in-Human, Phase 1b/2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma | Glioblastoma, Adult | completed | 100 |
| 2024-03-04 | P2 | Gilead Sciences GILD | NCT04778410 Study of Magrolimab Combinations in Participants With Myeloid Malignancies | Myeloid Malignancies | terminated | 54 |
| 2024-03-04 | P3 | Lyra Therapeutics | NCT05219968 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults | Chronic Sinusitis; Chronic Rhinosinusitis (Diagnosis) | completed | 196 |
| 2024-03-04 | P2 | Eli Lilly and Company LLY | NCT05256654 A Study of LY3561774 in Participants With Mixed Dyslipidemia | Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Hyperlipoproteinemia | completed | 205 |
| 2024-03-04 | P2 | Hoffmann-La Roche | NCT05307679 A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome | Dup15q Syndrome | terminated | 7 |
| 2024-03-04 | P2 | Eucure (Beijing) Biopharma Co., Ltd | NCT05420324 A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma | Mucosal Melanoma | completed | 20 |
| 2024-03-04 est. | P3 | IBSS Biomed S.A. | NCT05480462 Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria. | Diphtheria; Tetanus | unknown | 200 |
| 2024-03-04 | P3 | Alvotech Swiss AG ALVO | NCT05842213 Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX | Rheumatoid Arthritis | completed | 502 |
| 2024-03-04 | P1/P2 | Burgeon Therapeutics Co., Ltd. | NCT06491576 A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis | NASH | completed | 48 |
| 2024-03-05 | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT05733533 A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough | Refractory Chronic Cough | completed | 97 |
| 2024-03-05 | P3 | Seqirus | NCT06015282 The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | Influenza, Human | completed | 7741 |
| 2024-03-06 | P3 | Boehringer Ingelheim | NCT01853826 An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell | Carcinoma, Non-Small-Cell Lung | completed | 481 |
| 2024-03-06 | P3 | Kolon TissueGene, Inc. | NCT03291470 Study to Determine the Efficacy and Safety of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee | Degenerative Osteoarthritis | completed | 531 |
| 2024-03-06 | P2 | Cumberland Pharmaceuticals CPIX | NCT03340675 Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy Cardiomyopathy; Cardiomyopathy, Dilated | completed | 46 |
| 2024-03-06 | P3 | Eurofarma Laboratorios S.A. | NCT04721548 Treatment of Androgenetic Alopecia in Men for 24 Weeks | Alopecia | completed | 336 |
| 2024-03-06 | P2 | Sanofi SNY | NCT05245071 Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA | Non-squamous Non-small Cell Lung Cancer | terminated | 22 |
| 2024-03-06 | P2 | SOTIO Biotech AG | NCT05619172 A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer | Colorectal Cancer | terminated | 16 |
| 2024-03-06 | P3 | Merck Sharp & Dohme LLC MRK | NCT05665595 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melano | Melanoma | terminated | 1594 |
| 2024-03-06 | P2 | Zomagen Biosciences Ltd. | NCT05812781 A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome | Cryopyrin Associated Periodic Syndrome | completed | 7 |
| 2024-03-06 | P3 | Novo Nordisk A/S NVO | NCT05823948 A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS | Diabetes Mellitus, Type 2 | completed | 51 |
| 2024-03-06 | P2 | Dr. August Wolff GmbH & Co. KG Arzneimittel | NCT05863104 Assessment of Safety, Tolerability, Systemic Exposure and Efficacy of GPB Cream in Adolescents With Severe Primary Hyperhidrosis | Primary Axillary Hyperhidrosis | completed | 44 |
| 2024-03-06 | P3 | Colgate Palmolive CL | NCT06366568 Efficacy of a Eugenol-based Product to Improve the Quality of Toothbrushing and Relieving Gum Discomfort Areas | Plaque, Dental | completed | 86 |
| 2024-03-07 | P2 | Zenith Epigenetics | NCT03901469 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | Triple Negative Breast Cancer | terminated | 115 |
| 2024-03-07 | P2 | Contera Pharma | NCT03956979 A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia | Dyskinesias | completed | 89 |
| 2024-03-07 | P2 | Novartis Pharmaceuticals NVS | NCT04795466 Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease | Mild Cognitive Impairment; Alzheimer Disease | terminated | 34 |
| 2024-03-07 | P2 | Vifor (International) Inc. | NCT04817670 Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease | Sickle Cell Disease | completed | 25 |
| 2024-03-07 | P3 | AstraZeneca AZN | NCT04847232 Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALI | Hyperkalemia | terminated | 2690 |
| 2024-03-07 | P2 | TRYP Therapeutics | NCT05035927 Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder | Binge Eating Disorder | completed | 5 |
| 2024-03-07 | P2 | Sanofi SNY | NCT05237284 Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) | Amyotrophic Lateral Sclerosis | terminated | 305 |
| 2024-03-07 | P2 | Crinetics Pharmaceuticals Inc. | NCT05361668 Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome | Carcinoid Syndrome; Carcinoid; Carcinoid Tumor; Carcinoid Tumor of Ileum; Carcinoid Tumor of Cecum; | completed | 36 |
| 2024-03-07 | P3 | Laboratoires Thea | NCT05397600 Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients | Glaucoma; Ocular Hypertension | completed | 684 |
| 2024-03-07 | P3 | Taisho Pharmaceutical Co., Ltd. | NCT05461352 Long-Term Study of TS-142 in Patients with Insomnia | Patients with Insomnia | completed | 401 |
| 2024-03-07 | P3 | Huons Biopharma | NCT05964257 To Evaluate the Efficacy and Safety of LIZTOX in Subjects with Benign Masseteric Hypertrophy | Benign Masseteric Hypertrophy | unknown | 188 |
| 2024-03-08 | P2 | Taiho Oncology, Inc. | NCT04601857 Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma | Advanced and Metastatic Urothelial Cancer | terminated | 43 |
| 2024-03-08 | P2 | UCB Biopharma SRL | NCT04875975 A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Ence | Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis | terminated | 12 |
| 2024-03-08 est. | P3 | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | NCT06044077 A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People | Pneumococcal Disease | recruiting | 1920 |
| 2024-03-08 est. | P2 | Xizang Haisco Pharmaceutical Co., Ltd | NCT06290375 A Study of HSK21542 in a Peritoneal Dialysis Pruritus Population. | Pruritus | unknown | 250 |
| 2024-03-10 | P1/P2 | BiomX, Inc. | NCT05010577 Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection | Chronic Pseudomonas Aeruginosa Infection; Cystic Fibrosis | completed | 43 |
| 2024-03-11 | P2 | Immutep S.A.S. IMMP | NCT04811027 Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC | HNSCC | completed | 171 |
| 2024-03-11 | P3 | Novo Nordisk A/S NVO | NCT05053139 A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors | Haemophilia A; Haemophilia A With Inhibitors | completed | 281 |
| 2024-03-11 | P3 | Pfizer PFE | NCT05248997 Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis | Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps | completed | 261 |
| 2024-03-11 | P1/P2 | ImmunityBio, Inc. IBRX | NCT05370040 THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines | COVID-19 | terminated | 60 |
| 2024-03-11 | P2 | Neurocrine Biosciences NBIX | NCT05493293 Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures | Focal Onset Seizure; Focal Onset Epilepsy | terminated | 82 |
| 2024-03-11 | P3 | Beijing Konruns Pharmaceutical Co., Ltd. | NCT05970783 A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease | Chronic Pelvic Pain | unknown | 414 |
| 2024-03-12 | P3 | Zambon SpA | NCT03656926 Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2) | Bronchiolitis Obliterans; Chronic Rejection of Lung Transplant; Lung Transplant Rejection; Lung Tran | completed | 169 |
| 2024-03-12 | P3 | Shineway Pharmaceutical Co.,Ltd | NCT03789760 The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule | Vascular Dementia | completed | 493 |
| 2024-03-12 | P2 | GlaxoSmithKline | NCT04420221 Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 6 | Infections, Soft Tissue | completed | 226 |
| 2024-03-12 | P2 | Sanofi SNY | NCT04524689 Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based | Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) | terminated | 57 |
| 2024-03-12 | P2 | Advanced Accelerator Applications | NCT04711135 Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs | Gastroenteropancreatic Neuroendocrine Tumors; Pheochromocytoma; Paraganglioma | active not recruiting | 11 |
| 2024-03-12 | P3 | Novartis Pharmaceuticals NVS | NCT04948333 Asciminib Treatment Optimization in ≥ 3rd Line CML-CP | Chronic Myelogenous Leukemia | completed | 199 |
| 2024-03-12 | P2/P3 | Holostem s.r.l. | NCT05111600 Open-label, Pivotal Clinical Trial to Confirm Efficacy and Safety of Autologous Grafts Containing Stem Cells Genetically Modified for Epidermis Restoration in P | Junctional Epidermolysis Bullosa Non-Herlitz Type | terminated | 2 |
| 2024-03-12 | P3 | Eli Lilly and Company LLY | NCT05412004 Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea | Obstructive Sleep Apnea; Obesity | completed | 469 |
| 2024-03-12 | P3 | Pfizer PFE | NCT05540522 A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older | Influenza, Human | completed | 45789 |
| 2024-03-12 | P3 | Merck Sharp & Dohme LLC MRK | NCT05818137 A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020) | Pulmonary Arterial Hypertension | completed | 46 |
| 2024-03-13 | P2 | IntelGenx Corp. | NCT03402503 Safety, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease | Alzheimer Disease | completed | 52 |
| 2024-03-13 | P3 | Teva Branded Pharmaceutical Products R&D, Inc. | NCT04458857 A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age | Migraine | completed | 235 |
| 2024-03-13 est. | P3 | Eli Lilly and Company LLY | NCT04469062 A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis | Ulcerative Colitis | withdrawn | |
| 2024-03-13 | P2 | Novartis Pharmaceuticals NVS | NCT04926831 Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC | Non-small Cell Lung Cancer | terminated | 4 |
| 2024-03-13 | P2 | Gannex Pharma Co., Ltd. | NCT05190523 Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis | Primary Biliary Cholangitis | completed | 98 |
| 2024-03-13 | P3 | UCB Biopharma SRL | NCT05514873 An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Pr | Generalized Myasthenia Gravis | completed | 26 |
| 2024-03-13 | P2 | Pfizer PFE | NCT05546476 Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 | Non-small Cell Lung Cancer; Pancreatic Cancer; Colorectal Cancer; Loss of Appetite; Fatigue; Cachexi | completed | 187 |
| 2024-03-13 | P2 | Brii Biosciences Limited | NCT06057012 A Study of BRII-296 in Adults With Severe Postpartum Depression (PPD) | Severe Postpartum Depression | completed | 11 |
| 2024-03-13 | P3 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT06817187 Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine | Streptococcus Pneumoniae Infections | completed | 1110 |
| 2024-03-14 | P1/P2 | Cantargia AB | NCT03267316 A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | Non Small Cell Lung Cancer; Pancreatic Ductal Adenocarcinoma; Triple Negative Breast Cancer; Colorec | completed | 167 |
| 2024-03-14 | P2 | Insmed Incorporated INSM | NCT05176951 A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstit | Pulmonary Hypertension | completed | 39 |
| 2024-03-14 | P1/P2 | Enlivex Therapeutics RDO Ltd. ENLV | NCT05431907 Phase 1/2 Study Evaluating Safety and Potential Efficacy of Allocetra-OTS Via Pressurized Intra-Peritoneal Aerosol Chemotherapy as Add-on to Standard of Care Ch | Peritoneal Metastases | terminated | 9 |
| 2024-03-14 | P2 | Eli Lilly and Company LLY | NCT05563246 A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events | Lipoprotein Disorder | completed | 233 |
| 2024-03-14 | P3 | Tasly Biopharmaceuticals Co., Ltd. | NCT05700591 rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2) | Acute Ischemic Stroke | completed | 1552 |
| 2024-03-14 | P2 | Bio 54, LLC | NCT06205615 Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B | Wound Bleeding | completed | 24 |
| 2024-03-15 | P2 | CellProthera | NCT02669810 EXCELLENT (EXpanded CELL ENdocardiac Transplantation) | Acute Myocardial Infarction | completed | 49 |
| 2024-03-15 | P1/P2 | Eli Lilly and Company LLY | NCT04238819 A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neurob | Relapsed Solid Tumor; Refractory Solid Tumor | completed | 47 |
| 2024-03-15 | P2/P3 | ModernaTX, Inc. | NCT04796896 A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age | SARS-CoV-2 | completed | 11942 |
| 2024-03-15 | P3 | Laboratorios Silanes S.A. de C.V. | NCT04841096 Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure | Type 2 Diabetes | completed | 162 |
| 2024-03-15 | P3 | Axsome Therapeutics, Inc. AXSM | NCT05059223 A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy | Narcolepsy; Cataplexy; Excessive Daytime Sleepiness | completed | 90 |
| 2024-03-15 | P3 | Teva Pharmaceuticals USA | NCT05617820 Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal At | Dyspareunia | completed | 1050 |
| 2024-03-15 | P3 | Synlogic SYBX | NCT05764239 Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) | Phenylketonuria | terminated | 35 |
| 2024-03-17 | P1/P2 | Sonnet BioTherapeutics | NCT05435742 SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN) | Chemotherapy-induced Peripheral Neuropathy (CIPN) | terminated | 9 |
| 2024-03-18 | P3 | AstraZeneca AZN | NCT04494425 Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer | Advanced or Metastatic Breast Cancer | active not recruiting | 866 |
| 2024-03-18 | P2 | Bayer | NCT04722991 Non-proliferative Diabetic Retinopathy Treated With Runcaciguat | Diabetic Retinopathy | completed | 109 |
| 2024-03-18 | P3 | Tasly GeneNet Pharmaceuticals Co., Ltd | NCT05092841 A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A | Charcot-Marie-Tooth Type 1A | completed | 176 |
| 2024-03-18 | P3 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT05450887 Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis | Primary Biliary Cholangitis | completed | 108 |
| 2024-03-18 | P3 | Sollis Therapeutics, Inc. | NCT05614648 Sciatica Epidural Radiculopathy Experimental New Interventional TherapY Clonidine Micropellet | Lumbosacral Radiculopathy | terminated | 17 |
| 2024-03-18 | P2 | Intuitive Surgical ISRG | NCT05769257 A Safety and Feasibility Study of IS-001 Injection in Patients Undergoing Robotic Colorectal Surgery | Ureter Injury | completed | 12 |
| 2024-03-18 | P3 | Pfizer PFE | NCT05842967 A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease | RESPIRATORY SYNCYTIAL VIRUS (RSV) | completed | 885 |
| 2024-03-18 | P3 | Glaukos Corporation GKOS | NCT06061718 Travoprost Intraocular Implant in Conjunction With Cataract Surgery | Open Angle Glaucoma; Ocular Hypertension | unknown | 60 |
| 2024-03-19 | P3 | Biofrontera Inc. BFRI | NCT03573401 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic | Superficial Basal Cell Carcinoma | active not recruiting | 187 |
| 2024-03-19 est. | P2 | MedImmune LLC | NCT04145193 Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC | Microsatellite-stable Colorectal Cancer | withdrawn | |
| 2024-03-19 | P3 | Hoffmann-La Roche | NCT04285567 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Benda | Chronic Lymphocytic Leukemia (CLL) | completed | 166 |
| 2024-03-19 | P2 | 10xBio, LLC | NCT05154955 A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat | Submental Fat | completed | 51 |
| 2024-03-19 | P3 | Novo Nordisk A/S NVO | NCT05352815 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People | Diabetes Mellitus, Type 2 | completed | 1291 |
| 2024-03-19 | P3 | AbbVie ABBV | NCT05601882 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants Wit | Atopic Dermatitis | completed | 920 |
| 2024-03-19 | P3 | Teva Branded Pharmaceutical Products R&D LLC | NCT05693935 A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With S | Schizophrenia | completed | 675 |
| 2024-03-19 | P2 | PharmaMar | NCT05705167 Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA) | COVID-19 | terminated | 37 |
| 2024-03-19 | P3 | Chengdu Brilliant Pharmaceutical Co., Ltd. | NCT06092684 The Efficacy and Safety of Esketamine in Elective Laparoscopic Surgery | Laparoscopy; Anesthesia, Intravenous | completed | 358 |
| 2024-03-20 | P1/P2 | Imugene Limited | NCT02795988 A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer | Gastrointestinal Neoplasms; Adenocarcinoma | completed | 64 |
| 2024-03-20 | P3 | Merck Sharp & Dohme LLC MRK | NCT03615326 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junct | Gastric Neoplasms; Gastroesophageal Junction Adenocarcinoma | completed | 738 |
| 2024-03-20 | P2 | Novartis Pharmaceuticals NVS | NCT04589650 Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum | PIK3CA-related Overgrowth Spectrum (PROS) | active not recruiting | 236 |
| 2024-03-20 | P1/P2 | Lepu Biopharma Co., Ltd. | NCT04843709 A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors | Advanced or Metastatic Solid Tumors | completed | 39 |
| 2024-03-20 | P2 | Novartis Pharmaceuticals NVS | NCT05135000 Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | terminated | 47 |
| 2024-03-21 | P1/P2 | Hoffmann-La Roche | NCT03037385 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advance | RET-altered Non Small Cell Lung Cancer; Medullary Thyroid Cancer; RET-altered Papillary Thyroid Canc | completed | 590 |
| 2024-03-21 | P2/P3 | Pfizer PFE | NCT04804033 A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention | Migraine | terminated | 1753 |
| 2024-03-21 | P2 | TYK Medicines, Inc | NCT05146219 Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation | NSCLC; EGFR Activating Mutation; Brain Metastases; Leptomeningeal Metastasis | completed | 29 |
| 2024-03-21 | P3 | Endo USA Inc., a Keenova Therapeutics Company | NCT05254457 Long-Term Safety, Efficacy, and Durability of EN3835 in the Treatment and Retreatment of Plantar Fibromatosis | Plantar Fibromatosis | completed | 145 |
| 2024-03-21 | P3 | Sumitomo Pharma Co., Ltd. | NCT05359081 A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan | Schizophrenia | terminated | 68 |
| 2024-03-21 | P3 | JW Pharmaceutical | NCT05814406 To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM | Type 2 Diabetes Mellitus | completed | 196 |
| 2024-03-22 | P2 | Yiviva Inc. | NCT04000737 YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | Advanced Hepatocellular Carcinoma | completed | 62 |
| 2024-03-22 | P3 | Bristol-Myers Squibb BMY | NCT04026412 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Sur | Non-Small Cell Lung Cancer (NSCLC) | completed | 925 |
| 2024-03-22 | P3 | Yisheng Biopharma (Singapore) Pte. Ltd. | NCT05667974 A Study to Evaluate a PIKA Rabies Vaccine(Vero Cell)for Human Use,Freeze-dried | Rabies; Prevention | unknown | 4500 |
| 2024-03-22 | P3 | Chong Kun Dang Pharmaceutical | NCT06121518 Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy | Essential Hypertension | completed | 235 |
| 2024-03-25 | P1/P2 | Gilead Sciences GILD | NCT02953509 Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Non Hodgkin Lymphoma | terminated | 178 |
| 2024-03-25 | P1/P2 | Akeso | NCT03852251 A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ Adenocarci | Gastric Adenocarcinoma; Advanced Solid Tumors; Gastroesophageal Junction Adenocarcinoma | completed | 338 |
| 2024-03-25 | P2 | Vir Biotechnology, Inc. VIR | NCT04412863 Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | completed | 84 |
| 2024-03-25 | P3 | argenx ARGX | NCT04598477 A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) | Pemphigus Vulgaris; Pemphigus Foliaceus | terminated | 183 |
| 2024-03-25 | P2 | Tsumura USA | NCT04742907 Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection | Enhanced Recovery After Surgery | completed | 402 |
| 2024-03-25 | P3 | Gilead Sciences GILD | NCT04778397 Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patient | Acute Myeloid Leukemia | terminated | 258 |
| 2024-03-25 est. | P2 | Merck Sharp & Dohme LLC MRK | NCT05130086 A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035) | Human Immunodeficiency Virus (HIV) Infections | withdrawn | |
| 2024-03-25 est. | P2 | Ferring Pharmaceuticals | NCT05571111 Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After | Infertility | withdrawn | |
| 2024-03-25 | P2 | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | NCT05896527 A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | completed | 229 |
| 2024-03-25 | P2 | Chengdu Suncadia Medicine Co., Ltd. | NCT06051357 Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria | Paroxysmal Nocturnal Hemoglobinuria | completed | 26 |
| 2024-03-26 | P2/P3 | Staidson (Beijing) Biopharmaceuticals Co., Ltd | NCT04449588 Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS | COVID-19 Pneumonia | terminated | 369 |
| 2024-03-26 | P2 | Incyte Corporation INCY | NCT04629339 Study of INCB086550 in Select Solid Tumors | Non Small Cell Lung Cancer; Urothelial Cancer; Renal Cell Carcinoma; Hepatocellular Carcinoma; Melan | terminated | 16 |
| 2024-03-26 | P3 | Vertanical GmbH | NCT04940741 Efficacy and Safety of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain | Chronic Non-specific Low Back Pain | completed | 820 |
| 2024-03-26 | P2/P3 | BioNTech SE BNTX | NCT05472038 A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals | SARS-CoV-2 Infection; COVID-19 | completed | 1453 |
| 2024-03-26 | P3 | AstraZeneca AZN | NCT05573464 A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chr | Chronic Obstructive Pulmonary Disease (COPD) | completed | 559 |
| 2024-03-26 | P2 | Equillium EQ | NCT05589610 Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata | Alopecia Areata; Alopecia; Alopecia Totalis; Alopecia Universalis | completed | 36 |
| 2024-03-26 | P3 | JW Pharmaceutical | NCT05815901 A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients | Gout | completed | 612 |
| 2024-03-27 | P3 | Pfizer PFE | NCT03000439 A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA | Arthritis Juvenile Idiopathic | completed | 100 |
| 2024-03-27 | P2 | Altimmune, Inc. ALT | NCT04684914 HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) | Hepatitis B, Chronic | terminated | 87 |
| 2024-03-27 | P3 | Paratek Pharmaceuticals Inc | NCT04779242 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia | Community-acquired Pneumonia; Bacterial Pneumonia | completed | 670 |
| 2024-03-27 | P2/P3 | AstraZeneca AZN | NCT04986202 Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% | Heart Failure With Preserved Ejection Fraction | completed | 711 |
| 2024-03-27 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT05437510 Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and | RSV Immunization; Healthy Volunteer | completed | 8057 |
| 2024-03-27 | P3 | Huahui Health | NCT05787418 HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2 | COVID-19 | completed | 918 |
| 2024-03-27 est. | P2 | ImmuneMed, Inc. | NCT05808335 A Study to Assess the Efficacy and Safety of Burfiralimab(hzVSF-v13) and OAD (Oral Antiviral Drug) | Chronic Hepatitis B | unknown | 32 |
| 2024-03-27 | P2 | Oculis OCS | NCT05896670 Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease | Dry Eye Disease | completed | 122 |
| 2024-03-28 | P2 | TBF Genie Tissulaire | NCT05207189 Biological Sling Allograft (UVT) for the Treatment of Urinary Incontinence in Women Presenting With Synthetic Sling Complications | Female Stress Incontinence; Stress Urinary Incontinence | completed | 16 |
| 2024-03-28 | P1/P2 | Sanofi Pasteur, a Sanofi Company SNY | NCT05624606 Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older | Influenza Immunization | completed | 682 |
| 2024-03-28 | P1/P2 | Dermaliq Therapeutics, Inc. | NCT05636904 Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men | Androgenetic Alopecia | completed | 120 |
| 2024-03-28 est. | P2 | Keymed Biosciences Co.Ltd | NCT05671445 The Study of CM326 in Adult Subjects With Atopic Dermatitis | Atopic Dermatitis | unknown | 100 |
| 2024-03-29 | P3 | Ferring Ventures Limited | NCT03710876 Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma | Malignant Pleural Mesothelioma | completed | 53 |
| 2024-03-29 | P1/P2 | Keymed Biosciences Co.Ltd | NCT05324137 A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis With Nasal Polyps | completed | 88 |
| 2024-03-29 est. | P2 | Shanghai Henlius Biotech | NCT05354700 A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer | Small-cell Lung Cancer | unknown | 20 |
| 2024-03-29 | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT05601778 A Study of HSK31858 in Participants with Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis (NCFBE) | completed | 226 |
| 2024-03-29 | P2/P3 | AstraZeneca AZN | NCT05648110 Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anit | COVID-19, SARS-CoV-2 | completed | 3882 |
| 2024-03-29 | P2 | Janssen Research & Development, LLC | NCT05663866 Premedication to Reduce Amivantamab Associated Infusion Related Reactions | Carcinoma, Non-Small-Cell Lung | active not recruiting | 68 |
| 2024-03-29 | P3 | Chongqing Claruvis Pharmaceutical Co., Ltd. | NCT06499688 A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines | Moderate to Severe Glabellar Lines | completed | 529 |
| 2024-03-30 | P3 | Marinus Pharmaceuticals | NCT04391569 Randomized Therapy In Status Epilepticus | Status Epilepticus | completed | 100 |
| 2024-03-30 | P2 | Vicore Pharma AB | NCT04533022 Safety, Efficacy and Pharmacokinetics of C21 in Subjects With IPF | Idiopathic Pulmonary Fibrosis | completed | 52 |
| 2024-03-30 | P2 | Juventas Cell Therapy Ltd. | NCT04586478 Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | recruiting | 60 |
| 2024-03-30 | P2 | IMMUNOe Research Centers | NCT04705831 Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection | Post-Viral Fatigue Syndrome; Post-Viral Disorder (Disorder); Covid19 | completed | 40 |
| 2024-03-30 | P1/P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT04856774 Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors | Advanced Solid Tumors | completed | 81 |
| 2024-03-30 est. | P2 | Veru Inc. VERU | NCT05079360 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer | Metastatic Breast Cancer | withdrawn | |
| 2024-03-30 est. | P2 | Jiangsu HengRui Medicine Co., Ltd. | NCT05333835 A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes | Type 2 Diabetes | unknown | 455 |
| 2024-03-30 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT05799820 QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | Colorectal Carcinoma | unknown | 60 |
| 2024-03-31 | P3 | GlycoMimetics Incorporated | NCT03616470 Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia | terminated | 388 |
| 2024-03-31 est. | P2 | Dascena | NCT03752489 Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment | Sepsis; Severe Sepsis; Septic Shock | unknown | 51645 |
| 2024-03-31 | P3 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | NCT04143607 ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC | Locally Advanced or Metastatic NSCLC | unknown | 337 |
| 2024-03-31 est. | P2 | SCM Lifescience Co., LTD. | NCT04189432 Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease | Chronic Graft-versus-host-disease | unknown | 84 |
| 2024-03-31 est. | P3 | Eidos Therapeutics, a BridgeBio company | NCT04418024 Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy | Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy | withdrawn | |
| 2024-03-31 est. | P2 | Cyclo Therapeutics, Inc. | NCT05607615 A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease | Alzheimer's Disease | unknown | 90 |
| 2024-03-31 est. | P1/P2 | Kang Stem Biotech Co., Ltd. | NCT05944627 Evaluate Safety and Explore Efficacy of FURESTEM-OA Kit Inj. in Patients With Knee Osteoarthritis | Knee Osteoarthritis | unknown | 68 |
| 2024-03-31 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT06228586 Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam | Meningococcal Infection; Healthy Volunteers | completed | 447 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.